Mendelian randomization reveals CD127 on CD8+ Treg cells mediates GDF-15's impact on sarcopenia, suggesting treatment innovation.
Growth Differentiation Factor 15 (GDF-15) is closely associated with the occurrence and progression of sarcopenia, but the causal relationship between GDF-15 and sarcopenia remains unclear, and it is also uncertain whether immune cells mediate the pathway between GDF-15 and sarcopenia. We employed Mendelian randomization analysis to explore the causal relationship between GDF-15 and sarcopenia, using the inverse variance-weighted (IVW) method as the primary analytical approach, and validated the results through sensitivity analyses. In addition, we explored whether 731 immune cell phenotypes mediate these causal relationships. GDF-15 was negatively correlated with all four traits of sarcopenia, specifically with whole body fat-free mass (odds ratio [OR] = 0.989, 95% confidence interval [CI] = 0.979-0.998, pIVW = 2.149E-02), left arm fat-free mass (OR = 0.988, 95% CI = 0.979-0.998, pIVW = 1.345E-02), right arm fat-free mass (OR = 0.987, 95% CI = 0.979-0.995, pIVW = 1.091E-03), and appendicular lean mass (OR = 0.984, 95% CI = 0.974-0.993, pIVW = 7.658E-04). Mediation analysis indicated that CD127 on CD28+ CD45RA+ CD8br mediated the causal relationship between GDF-15 and sarcopenia, with a mediation proportion of 21.58% (p = 0.023). In conclusion, our study proposed that CD127 on CD28+ CD45RA+ CD8br mediates the causal relationship between GDF-15 and sarcopenia, providing potential theoretical support and practical guidance for the innovation of treatment strategies and personalized therapies for sarcopenia.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: